Purepac Glucophage XR ANDA Status Could Factor Into Injunction Ruling
Executive Summary
A D.C. federal judge's decision on whether Ivax should be preliminarily enjoined from immediately marketing its generic version of Glucophage XR could hinge on the imminent approvability of Purepac's ANDA for metformin extended-release
You may also be interested in...
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Ivax Glucophage XR Generic Exclusivity Rights Questioned By Judge
FDA's rationale for awarding Glucophage XR generic marketing exclusivity to Ivax rather than Purepac received a skeptical hearing from a federal judge Nov. 12